Zevra Therapeutics, Inc.
ZVRA
$8.31
$0.374.66%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -129.13% | -339.38% | -301.09% | -29.72% | -72.00% |
| Total Depreciation and Amortization | 535.09% | 965.13% | 364.68% | 159.81% | 6.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 541.72% | 236.58% | 129.43% | -69.86% | -25.17% |
| Change in Net Operating Assets | -212.87% | -136.68% | 35.37% | -113.39% | 1,549.01% |
| Cash from Operations | -107.74% | -218.57% | -135.46% | -137.68% | -79.17% |
| Capital Expenditure | -- | 72.09% | -114.04% | -151.89% | -218.28% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -115.76% | -115.76% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -266.54% | 187.72% | -31.93% | 225.93% | 159.05% |
| Cash from Investing | -27.44% | 78.23% | -215.08% | 129.66% | 52.64% |
| Total Debt Issued | 37.51% | 59.03% | 538.18% | 14.03% | 210.43% |
| Total Debt Repaid | -138.29% | -246.78% | -230.58% | 66.39% | -1,269.14% |
| Issuance of Common Stock | 963.54% | 22,091.74% | 2,766.79% | 2,227.47% | 1,851.85% |
| Repurchase of Common Stock | -- | 100.00% | 100.00% | 100.00% | 27.02% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -3,175.00% | -3,175.00% | -- | -- |
| Cash from Financing | 188.46% | 272.00% | 1,479.80% | 258.13% | 240.80% |
| Foreign Exchange rate Adjustments | 931.82% | 213.79% | 52,000.00% | -124.54% | -78.43% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 58.67% | 140.20% | -154.52% | 104.44% | 52.18% |
